Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
27.17(c) 26.21(c) 25.76(c) 25.53(c) 25.01(c) Last
3 669 915 4 377 689 6 991 727 1 939 471 2 895 530 Volume
-3.79% -3.53% -1.72% -0.89% -2.04% Change
More quotes
Financials ($)
Sales 2017 1,54 M
EBIT 2017 -114 M
Net income 2017 -121 M
Finance 2017 268 M
Yield 2017 -
Sales 2018 36,6 M
EBIT 2018 -113 M
Net income 2018 -116 M
Finance 2018 202 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 435x
EV / Sales2018 20,1x
Capitalization 937 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies.The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis.It offers products under the Zilretta brand.The company... 
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
10/12 FLEXION THERAPEUTICS, INC. (NASDAQ : FLXN) Files An 8-K Financial Statements and..
10/12 FLEXION THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form..
10/11 Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
10/11 FLEXION THERAPEUTICS : Zilretta approval in hand, lays out roadmap to blockbuste..
10/10 FLEXION THERAPEUTICS INC : Results of Operations and Financial Condition, Other ..
10/10 Flexion Therapeutics Announces Proposed Public Offering of Common Stock
10/10 OSTEOARTHRITIC KNEE PAIN THERAPY FLE : FLXN) Zilretta Approved By The FDA
10/09 FLEXION THERAPEUTICS TO HOLD CONFERE : 00 a.m. ET to Discuss Recent FDA Approval..
10/09 FLEXION THERAPEUTICS TO HOLD CONFERE : 00 a.m. ET to Discuss Recent FDA Approval..
10/09 FLEXION THERAPEUTICS, INC. (NASDAQ : FLXN) Files An 8-K Financial Statements and..
More news
Sector news : Bio Therapeutic Drugs
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/14Laidlaw Reiterates Buy Rating for Flexion Therapeutics, Inc. $FLXN  
10/13Flexion Therapeutics, Inc. $FLXN Raised to Hold at Zacks Investment Research .. 
10/13Q3 Ends With A Bang, $ZGNX Surges 200% On Strong Data  
10/12Flexion Therapeutics $FLXN Getting Somewhat Favorable News Coverage, Accern R.. 
10/12$FLXN (-1.2% pre) Flexion Therapeutics Prices 4.8M Shares at $25.50 - SI
1
More tweets
Qtime:74
News from SeekingAlpha
10/13 Demand And Supply Of Stocks - Cramer's Mad Money (10/12/17)
10/12 BIOTECH ANALYSIS CENTRAL : Daily Pharma News - Oct. 12, 2017
10/12 Flexion Therapeutics prices public offering of common stock; shares off 1% pr..
10/11 YOUR DAILY PHARMA SCOOP : Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosu..
10/10 After Hours Gainers / Losers
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Technical analysis trends FLEXION THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 39,2 $
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer, CFO & Director
Patrick J. Mahaffy Chairman
Neil Bodick Chief Scientific Officer
Yamo Deniz Chief Medical Officer
Samuel D. Colella Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS INC34.23%937
GILEAD SCIENCES13.35%106 002
REGENERON PHARMACEUTICALS21.81%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910